Search research articles
Contact Us
Filters
Showing results (111-120 of 164) with videos related to
Page
of 17
Sort By:
Plos One
|
December 5, 2019
Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial
Patrice Forget, Gauthier Bouche, Francois P Duhoux, et al.
Clinical Genitourinary Cancer
|
December 12, 2018
Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib
Maxime Vanmechelen, Diether Lambrechts, Thomas Van Brussel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2010
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schöffski, Jean-Yves Blay, Jacques De Greve, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
Viktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
Targeted Oncology
|
October 12, 2014
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer
Feby Ingriani Mardjuadi, Javier Carrasco, Jean-Charles Coche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, et al.
Cancers
|
April 12, 2022
Unmet Needs and Perspectives in Oral Cancer Prevention
Jebrane Bouaoud, Paolo Bossi, Moshe Elkabets, et al.
The Oncologist
|
September 20, 2022
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
Niven Mehra, Karim Fizazi, Johann S de Bono, et al.
The Oncologist
|
May 22, 2012
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial
Bruno Coudert, Bernard Asselain, Mario Campone, et al.
Breast Cancer Research : BCR
|
April 17, 2020
Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families
Cédric Van Marcke, Raphaël Helaers, Anne De Leener, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 164) with videos related to
Sort By:
Page
of 17
Plos One
|
December 5, 2019
Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial
Patrice Forget, Gauthier Bouche, Francois P Duhoux, et al.
Clinical Genitourinary Cancer
|
December 12, 2018
Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib
Maxime Vanmechelen, Diether Lambrechts, Thomas Van Brussel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2010
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schöffski, Jean-Yves Blay, Jacques De Greve, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
Viktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
Targeted Oncology
|
October 12, 2014
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer
Feby Ingriani Mardjuadi, Javier Carrasco, Jean-Charles Coche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, et al.
Cancers
|
April 12, 2022
Unmet Needs and Perspectives in Oral Cancer Prevention
Jebrane Bouaoud, Paolo Bossi, Moshe Elkabets, et al.
The Oncologist
|
September 20, 2022
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
Niven Mehra, Karim Fizazi, Johann S de Bono, et al.
The Oncologist
|
May 22, 2012
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial
Bruno Coudert, Bernard Asselain, Mario Campone, et al.
Breast Cancer Research : BCR
|
April 17, 2020
Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families
Cédric Van Marcke, Raphaël Helaers, Anne De Leener, et al.
Page
of 17